Præliminære resultater fra cellebaserede analyser viste, at adefovir- resistensassocieret substitution A181V havde 3, 7 gange reduceret følsomhed for telbuvidin.
The preliminary results from the cell-based assay showed that the adefovir resistance-associated substitution A181V had 3.7 fold reduced susceptibility to telbivudine.